tailieunhanh - Intratumoral heterogeneity impacts the response to anti-neu antibody therapy

Along with de novo resistance, continued exposure to trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2/neu) antibody, can lead to acquired resistance. In this study, we characterize a new anti-HER2/neu antibody resistant and metastatic mouse breast carcinoma cell line, TUBO-P2J. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN